BBIO Stock Forecast & Price Target

BridgeBio Pharma has demonstrated a robust financial outlook, with an increase in its full-year 2026 revenue forecast to $766.3 million, indicating confidence in its late-stage pipeline, particularly driven by the anticipated growth of its key program, Attruby. The company has also seen a significant increase in the number of patients treated, with expectations that the patient count for Attruby will nearly double over the next five years. Additionally, the clinical data for other candidates in its pipeline suggests a favorable regulatory environment, which, combined with the growing market for transthyretin amyloid cardiomyopathy treatments, positions BridgeBio for continued revenue growth and market expansion.

BridgeBio Pharma is forecasting a significant net loss of $3.59 million for the full year of 2025, raising concerns about its financial sustainability amid escalating competition in the biotech space, exemplified by the recent launch of a competing drug by ALNY. The company faces multiple risks including clinical program execution challenges, regulatory uncertainties, and potential long-term pricing pressure, which could severely impact its pipeline value and market position. Additionally, the projected revenue from Attruby is expected to peak at $3 billion, but concerns over declining demand and limited patient switches due to high out-of-pocket costs suggest a tenuous future for the drug's commercial viability.